
    
      Patients are randomized to receive AZT alone, AZT and ddI, AZT and ddC, or ddI alone for at
      least 2 years. Patients who develop AIDS or whose CD4 count falls to 50 percent or less of
      baseline are crossed over to another treatment arm.

      PER AMENDMENT 4/5/95: Study treatment will be available until 10/31/95 at the latest for
      patients still taking study medications on 4/30/95, so that follow-up trials may be completed
      and approved.
    
  